Disease overview: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an incidence of 1-2 cases per 100 000 adults. It accounts for approximately 15% of newly diagnosed cases of leukemia in adults.
| Diagnosis
The diagnosis of typical CML is simple and consists of documenting, in the setting of persistent unexplained leukocytosis (or occasionally thrombocytosis), the presence of the Philadelphia (Ph) chromosome abnormality, the t(9;22)(q34;q11), by routine cytogenetics, or the Phrelated molecular BCR-ABL1 abnormalities by fluorescence in situ hybridization (FISH) or by molecular studies. [13] [14] [15] A FISH analysis relies on the colocalization of large genomic probes specific to the BCR and ABL genes. Comparison of simultaneous marrow and blood samples by FISH analysis shows high concordance.
FISH studies may have a false positive range of 1%-5% depending on the probes used. Bone marrow aspiration is mandatory for all patients in whom CML is suspected, as it will confirm the diagnosis (eg, cytogenetic analysis), and provide information needed for staging in terms of the blast and basophil percentages. Baseline cytogenetic analysis allows the detection of clonal evolution, particularly i(17)(q10)-7/del7q, and 3q26.2 rearrangements, associated with a relatively poor prognosis. 16 Baseline reverse transcriptase-polymerase chain reaction is imperative to identify the specific type of rearrangement that can be appropriately followed when assessing for response to TKI therapy. About 2%-5% of patients have e13a3 or e14a3 (not e13a2 or e14a2) variants of p210 BCR-ABL1 or p230 transcripts that may yield a false negative PCR by routine probes and (if not tested at diagnosis) would give the false impression that a patient is in "complete molecular response" on TKI. showing the Ph chromosome, the BCR-ABL1 rearrangement, or both lead to the appropriate diagnosis and treatment.
| Frontline treatment options
The three commercially available TKIs for the frontline treatment of CML include imatinib, dasatinib, and nilotinib. Current guidelines endorse all three as options for the initial management of CML in the chronic phase (CML-CP) ( Table 1 ).
| Imatinib
Imatinib mesylate was the first TKI to receive the Food and Drug Administration (FDA) approval for the treatment of patients with CML-CP. It acts via competitive inhibition at the ATP-binding site of the BCR-ABL1 oncoprotein, which results in the inhibition of phosphorylation of proteins involved in cell signal transduction. It also blocks the platelet-derived growth factor receptor and the C-KIT tyrosine kinase. 17 The International Randomized Study of Interferon and STI571 (IRIS) study is considered a landmark clinical trial for TKIs and CML. 18 Investigators randomized 1106 patients in CML-CP to receive imatinib 400 mg/day or IFN-a and low-dose cytarabine. After a median follow-up of 19 months, the outcomes for patients receiving imatinib were significantly better than those treated with IFN-a and cytarabine, notably the rates of complete cytogenetic response (CCyR) rate (74% versus. 9%, P < .001), and freedom-from-progression to AP or BP at 12 months (99% versus 93%, P < .001). Further highlighting the challenge of using IFN-a was the high crossover rate to imatinib due to intolerance. With a median follow-up of almost 11 years, the estimated overall survival rate for patients who had been assigned to receive imatinib was 83.3% with a cumulative CCyR rate of 83% and a 10-year major molecular response (MMR) rate of 93%. 19 Despite the high rate of early crossover among patients assigned to receive IFN-a and cytarabine, the 10-year survival rate favored the imatinib therapy arm (83.3% versus 78.8%).
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While the results using imatinib are impressive, only 48% of patients enrolled in the IRIS study remained on therapy at the 10-year follow-up time. This underscored the need for additional treatment options for patients who had resistance or intolerance to imatinib. This led to the rational development of second generation TKIs.
| Imatinib generics
Imatinib generics entered the market recently after the Novartis patent for Gleevec expired. Several groups have reported on the efficacy and safety of generic imatinib compared to the branded one. The Polish Adult Leukemia Group (PALG) imatinib generics registry reported on a large series of patients who started imatinib generic (multiple manufacturers) therapy after the diagnosis of CML (group A, n 5 99) or were switched to generic from branded imatinib (group B, n 5 627) and were observed for at least 12 months. 20 Among patients treated in the frontline setting (group A), the rates of 3-month partial cytogenetic response (PCyR), 6-month CCyR, and 12-month MMR were 66%, 53%, and 50%, respectively, similar to the expected rates with branded imatinib.
The rates of resistance and intolerance were also similar (26% and 28%, respectively). Among patients who switched therapy, responses were maintained in the vast majority, with only 0.3% and 1% of patients losing a CCyR and MMR, respectively. Similar data were reported from India. Among 174 patients treated with generics, response and survival rates were similar to those observed among 1193 patients treated with the branded imatinib. Safety profiles were similar as well. 21 
| High-dose imatinib and imatinib-based combinations
Other strategies for frontline therapy include using higher doses of imatinib or combining a TKI with an additional agent, such as IFN-a. In the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study, patients were randomized to receive imatinib 400 mg once daily or twice daily (800 mg). 22 MMR rate at 12 months was the study primary endpoint, with cytogenetic response and time to such responses collected as secondary outcomes. Patients in the high-dose group achieved faster CCyR and MMR, but the rates were not significantly different at 12 months.
Interferon has re-emerged as an interesting therapeutic option in CML with the advent of pegylated formulations requiring less frequent administration and showing improved tolerability. In a phase III randomized study, patients were assigned to one of four treatment arms: imatinib 400 mg once daily; imatinib 600 mg once daily; imatinib 400 mg once daily plus peginterferon alfa-2a; imatinib 400 mg once daily plus subcutaneous cytarabine. 23 Patients were initially assigned to receive peginterferon alfa-2a at a dose of 90 mcg once weekly.
Because of a high rate of discontinuation due to toxicity, the dose was later reduced to 45 mcg once weekly. At 12 months, the rates of CCyR were similar among the four groups. The imatinib plus peginterferon alfa-2a treated group obtained higher rates of MMR and deeper molecular responses, but follow-up was not sufficient to define the impact on long-term outcomes.
The CML-study IV explored whether treatment with imatinib 400mg/day (n 5 400) could be optimized by doubling the dose (n 5 420), adding interferon (n 5 430) or cytarabine (n 5 158) or using imatinib after interferon-failure (n 5 128). 24 From July 2002 to March 2012, 1551 newly diagnosed patients in CML-CP were randomized into a 5-arm study. The study was powered to detect a survival difference of 5% at 5 years. After a median observation time of 9.5 years, the 10-year overall survival rate was 82%, the 10-year progression-free survival rate was 80%, and the 10-year relative survival rate was 92%. In spite of a faster response with imatinib 800 mg, the survival difference between standard-dose and higher dose imatinib was only 3% at 5 years (less than 5%). In a multivariate analysis, standard-dose imatinib was equivalent to other "optimized "arms.
Patients who reached the 6-months BCR-ABL1 transcripts [IS] <10% milestone, had a significant survival advantage of about 6% after 10 years regardless of therapy.
| Dasatinib
Dasatinib is an oral, second generation TKI that is 350 times more potent than imatinib in vitro. [25] [26] [27] It also inhibits the Src family of kinases, which may be important in blunting critical cell signaling pathways. 28 Though initially evaluated in patients in the salvage setting, it was later compared to imatinib in frontline CML to test the possibility that frontline use of the more potent TKIs might improve outcomes.
The DASISION trial was a phase III randomized study comparing imatinib 400 mg once daily to dasatinib 100 mg once daily in newly diagnosed patients with CML. 29 The primary outcome was confirmed CCyR (cCCyR) at 12 months. A total of 519 patients were randomized A third phase III randomized study, SPIRIT 2, compared imatinib 400 mg daily with dasatinib 100 mg daily. 32 The primary endpoint of this trial is EFS at 5 years, with the rate of achievement of MMR, a key secondary endpoint. The interim results showed the 12-month MMR rates with dasatinib versus imatinib to be 58% versus 43% (P < .001). The 12-month CCyR rates were 51% and 40% respectively (P < .002). Progression rate to CML-AP was 0.7% with imatinib and 0.5% with dasatinib. The progression rate to CML-BP was 1.7% versus 1%.
Pleural effusions occurred more frequently on dasatinib (19% versus <1%). Other side effects of dasatinib included myelosuppression (20%), and rare pulmonary hypertension (1-2%).
| Lower dose dasatinib
In early clinical trials, dasatinib was found active at lower doses with better safety profile. 33 In a later randomized trial, dasatinib 100 mg daily was found as effective as 140 mg daily, with a better safety profile. 34 Furthermore investigators from the DASISION trial have reported on the ability to maintain efficacy of dasatinib among patients who had their dose reduced while improving its safety profile. 35 Based on this rationale, we treated 75 patients with early CML-CP with dasatinib 50 mg daily. 36 Ninety-five percent of patient treated achieved a 3-month PCyR. At 12 months, the MMR and molecular response 4.5 (MR4.5) rates were 83% and 74%. These rates compare favorably with historical data with dasatinib 100 mg daily. In addition, the safety profile was favorable; only one patient discontinued therapy (subdural hematoma unlikely related) and one patient had his dose reduced to 20 mg daily due to pleural effusion. Such strategy will have a significant impact on our future practice, mainly due equivalent efficacy, better safety profile, and lower cost.
| Nilotinib
Nilotinib is a structural analog of imatinib. Its affinity for the ATP binding site on BCR-ABL1 is 30-50 times more in vitro. 37 Like dasatinib, nilotinib initially demonstrated the ability to induce hematologic and cytogenetic responses in patients who had failed imatinib.
Similar to dasatinib, nilotinib was also compared to imatinib in a large, international, randomized study (ENEST-nd). In ENEST-nd, two doses of nilotinib (300 mg or 400 mg twice daily) were compared to imatinib 400 mg once daily. 38 The primary endpoint was the rate of MMR at 12 months. This endpoint was achieved at statistically significantly higher rates for both doses of nilotinib compared with imatinib (44% and 43% versus 22%, P < .001). The cumulative incidence of CCyR by 24 months was 87% with nilotinib 300 mg twice daily, 85%
with nilotinib 400 mg twice daily, and 77% with imatinib 400 mg daily (P < .001).
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With a minimum follow-up of 5 years, the two arms of nilotinib demonstrated better early results compared with imatinib. 39 The cumulative incidences of MMR by 60 months were 77%, 77%, and 60%, respectively (P < .0001%). The incidences of BCR-ABL1 transcripts
[IS] < 0.0032% (roughly equivalent to a 4.5 log reduction of disease) by 72 months were 54%, 52%, and 33%, respectively (P < .0001%). The incidences of transformation to AP or BP were 3.9%, 2.1%, and 7.4%, respectively (P 5 .06 and .003, respectively). The estimated 5-year EFS rates were not different, 95%, 97%, and 93%, respectively. The estimated 5-year survival rates were 94%, 96%, and 92%, respectively.
While nilotinib was superior to imatinib across all Sokal score catego- In a second randomized trial with the same design that enrolled 267 Chinese patients, the 12-month MMR rate was 52% with nilotinib compared with 28% with imatinib. 40 However, the rates of both CCyR (84% versus 87%) and progression-free survival (95% each) were similar at 24 months. In both arms, the estimated 2-year survival rate was 98%.
While nilotinib therapy was overall well tolerated, there was an increased risk of accumulated vascular events on therapy. The 6-year cumulative cardiovascular event rates were 9.9%, 15.9%, and 2.5%, among patients treated with nilotinib 300 mg twice daily, nilotinib 400 mg twice daily, and imatinib 400 mg daily, respectively. 39 Other notable side effects were headache and skin rashes (common 220-30%-but mild to moderate; alleviated by dose reduction), self-limited elevation of indirect bilirubin (10%), elevations of blood sugar (10%-20%), and rare pancreatitis (1%-2%).
| Bosutinib
Bosutinib is a potent dual SRC/ABL kinase inhibitor. The drug first approved for adults with CML resistant and/or intolerant to prior therapy. Bosutinib was recently evaluated for front-line treatment CML-CP. 41 In a multinational, phase III study, 536 patients with newly diagnosed chronic-phase CML were randomly assigned to receive 400 mg of bosutinib once daily (n 5 268) or imatinib (n 5 268). The major MMR rate at 12 months (primary end point) was significantly higher with bosutinib versus imatinib (47% versus 37%, respectively; P 5 .02), as was the CCyR rate by 12 months (77% versus 66%, respectively; P 5 .0075). Among treated patients, 22% of patients receiving bosutinib and 27% of patients receiving imatinib discontinued treatment, mostly for drug-related toxicity (13% and 9%, respectively). 41 Grade ! 3 diarrhea (8% versus 0.8%) and increased ALT (19% versus 1.5%) and AST (10% versus 2%) levels were more common with bosutinib. Cardiac and vascular toxicities were uncommon. Based on these results, bosutinib received an approval for frontline CML-CP therapy as of December 2017.
| The MD Anderson Cancer Center (MDACC) experience (Table 2)
We published the long-term responses and outcomes of patients with CML-CP and provided a comparison of four commonly used TKIs. 400 mg daily (n 5 68), imatinib 800 mg daily (n 5 200), dasatinib 50 mg twice daily or 100 mg daily (n 5 106), or nilotinib 400 mg twice daily (n 5 108). More patients receiving imatinib 800 mg or secondgeneration TKIs (ie, dasatinib or nilotinib) achieved CcyR: 87% for imatinib 400 mg; 90% for imatinib 800 mg; 96% for dasatinib; and 93% for nilotinib. The MMR rates were 76%, 86%, 90%, and 91%, respectively.
The 4Á5 log or higher reduction in BCR-ABL1 transcripts (MR4.5) response rates were 57%, 74%, 71%, and 71%, respectively. These findings were consistent over time (3-60 months); where at any time point, imatinib induced lower rates of cytogenetic and molecular responses. These landmark assessments contrast with previous reports where results are reported cumulatively ("by" not "at") and can be misleading. The 5-year event-free survival significantly differed between imatinib 400 mg and the other TKI groups (imatinib 800 mg P 5 .029, dasatinib P 5 .003, nilotinib P 5 .031). However, there was no significant difference in the 5-year failure-free survival (P 5 .32, P 5 .075, P 5 .332), transformation-free survival (P 5 .053, P 5 .038, P 5 .493), or overall survival (P 5 .563, P 5 .162, P 5 .981). We also compared eventfree and overall survival according to whether or not MMR or MR4.5
response was achieved in addition to CcyR. As expected, in patients who achieved CcyR, no difference in outcomes was observed regardless of whether MMR or MR4.5 response was achieved. with CML (e.g., age <50 years) versus older patients, may be entertained. 44 and patients with preexisting PAH may be considered for alternative TKIs in the frontline setting. Dasatinib also inhibits platelets function, 45 and patients taking concomitant anticoagulants may be at an increased risk of hemorrhagic complications. 46 Nilotinib has been associated with hyperglycemia. Caution should be exercised in patients with uncontrolled diabetes when initiating therapy, and avoided or prescribed with caution in patients with diabetes or history of pancreatitis. During preclinical development, nilotinib was shown to potentially prolong the QT interval, and parameters were put in place to monitor for this complication after the drug was approved; potassium and magnesium should be repleted to appropriate serum levels before starting nilotinib or determining an individual patient's QT interval. Patients should always be counseled to take nilotinib in a fasting state to avoid excess drug exposure. Nilotinib has also been associated with vasospastic and vaso-occlusive vascular events, such as ischemic heart disease, ischemic cerebrovascular events, and peripheral artery occlusive disease (PAOD). [47] [48] [49] [50] In the 6-year followup on the ENEST-nd trial, 39 approximately 10% of patients experienced vascular events. Nilotinib use should be limited in patients with risk factors such as diabetes mellitus or coronary or cerebrovascular artery disease. Avoiding nilotinib in patients with significant past vascular histories is warranted with the availability of other viable options. Nilotinib is also given twice daily on empty stomach; this may result in compliance issues.
| S EL E CTI N G A F RON TL I NE TH
Imatinib causes bothersome quality-of-life side-effects including weight gain, fatigue, peripheral and periorbital edema, bone and muscle aches, nausea and others. However, most are mild to moderate. Less than 5%-10% experience elevations in creatinine with long-term therapy.
Finally, the patient's age plays an important role in the treatment decision. Patients younger than 50 years are expected to live 301 more years. Therefore, inducing a durable CMR may potentially lead to therapy discontinuation. Second generation TKIs induce a significantly higher rate of CMR compared with imatinib. The issue of durable CMR and potential therapy discontinuation plays a less important role in elderly patients where the expected survival is shorter and discontinuing therapy is less relevant.
| Cost
The cost of cancer drugs has risen exponentially over the past decade. 51 All anticancer agents approved in the recent years were priced at over $120 000 annually. 51 When an international group of CML experts called attention to the high prices of TKIs, the cost history of imatinib was used to illustrate the problem with the high cancer drug prices. 52 When first approved in the United States, the annual price for imatinib was less than $30 000, the price set to make the development and commercialization of imatinib profitable based on cost of research, population at risk, competitive market, estimated profits, and estimated shorter-than-realized patient survival. Patients compliant with their treatment regimen now live a "normal" lifespan and remain on imatinib indefinitely. 53, 54 Paradoxically, with a higher number of patients and a longer duration of therapy, the annual price of imatinib had quadrupled to $132 000. This price is in the same range as dasatinib and nilotinib, both priced above $130 000/year of therapy.
In 2016, generic formulations of imatinib became available, although at a higher price than expected. This price should eventually fall dramatically below $5-8000/year (as in Canada; the annual price of generics in India is only $400). Physicians will then have to assess the "treatment value" of second generation TKI (dasatinib or nilotinib) in the frontline setting against the generic imatinib in relation to benefits versus cost. Second generation TKIs may be offered for patients with high-risk disease, while imatinib and/or its generic formulations will be offered for patients with low-risk disease. Experts recently assessed, following a Markov model, the most cost-effective strategy for treating newly diagnosed CML-CP after imatinib loses patent exclusivity. 55 They found that initiating imatinib as frontline treatment and treating in a stepwise approach, compared to physician choice, costs less and offer clinically-equivalent utility. In this analysis, the stepwise therapy was found to have an incremental cost-effectiveness ratio (ICER) of $227 136/Quality-adjusted life years. The ICER was favorable for stepwise therapy for each Sokal risk group. Furthermore, the efficacy and safety of generic imatinib was compared to the patented drug (previously discussed). Finally, lower dose dasatinib may offer the ultimate solution with at least equivalent efficacy compared to second generation TKIs but at a significant lower cost (50% of branded dasatinb 100 mg daily), a price comparable to generic formulation of imatinib.
| Disease characteristics
For patients with CML-CP it is common to use one of the available risk stratification scores, such as Sokal 56 
| Important points for monitoring and determining treatment failure
At baseline, all patients should undergo a bone marrow examination to establish the diagnosis, assess percentage of blasts and basophils, and perform cytogenetic analysis to confirm the presence of the Philadelphia chromosome and to exclude clonal evolution, particularly i (17) (q10) 27/del7q, and 3q26.2 rearrangements, associated with a relatively poor prognosis. 16 The current recommendation that patients have a follow up bone marrow study at 3, 6, and 12 months after starting therapy may no longer be necessary. 58 An alternative method to determine cytogenetic response is with the use of FISH and PCR on peripheral blood. If a patient is responding optimally, and the FISH study is negative at 6 or 12 months and or BCR-ABL1 transcripts [IS]
<1%, it may be reasonable to omit marrow exams, as the patient is likely to be in CCyR. 59, 60 For patients in durable CCyR receiving TKI therapy, periodic molecular monitoring using RT-Q-PCR is acceptable and useful, but may lead to erroneous changes in a well-tolerated and effective treatment due to discordant results between laboratories or even within the same laboratory. One strategy to minimize this is to use interphase FISH as a complementary diagnostic test along with the molecular test to detect possible false positive or negative results generated by either assay. 60 For patients in CCyR, the achievement and maintenance of a MMR is of debatable significance. Several studies evaluating patients receiving imatinib or second generation TKIs have found that patients in CCyR have similar survival regardless of whether or not they achieved MMR. 61, 62 Early molecular response has been shown to have strong prognostic value (Table 3) . This has been shown with each of the 3 TKIs used in the frontline setting. A BCR-ABL1 transcripts [IS] < 10% at 3 months separates patients into high and low risk categories for long term outcomes (i.e., progression, survival). 30, 39, 63, 64 The important question is:
how should we advise a patient who does not meet the 3-month benchmark? One option is to switch TKIs early, but there are no data indicating this will alter long-term outcome. Several experts suggested that a follow-up measurement at 6 months will help define patients clearly in need of a change in therapy. 58 This strategy has been retrospectively analyzed by several large groups with conflicting results.
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The results of two independent study groups have suggested that all patients with BCR-ABL1 transcripts > 10% at 3 months do not necessarily have an inferior outcome. about 6% after 10 years regardless of therapy. 24 Thus, it may be reasonable to change the TKI from imatinib to second generation TKI for BCR-ABL1 transcripts [IS] >10% after 6 months. 66 However, a similar situation in a patient on second generation TKI (dasatinib, nilotinib)
does not necessarily imply consideration of allo-SCT.
| When to switch therapy
The aim of therapy in CML should be the achievement of CCyR within 12 months and to continue to be in CCyR at any time beyond 12 months, especially with standard dose imatinib therapy. For second generation TKIs, CCyR may need to be achieved sooner for an optimal outcome, for example, within 6 months. 68 Patients who do not achieve a complete hematologic response by 3 months should be considered for a change in therapy (Tables 4 and 5 at 6 months, the chances of attaining CCyR are low, and a change of therapy might be in indicated. Furthermore, a 3-month value of 10%
[IS] may not be accurate: in a recent report in 1 sample collected at 3 months and tested 96 times, the mean value was 11% (range, 5%-16%), with only 31% of tests being 10%. 69 This approach also applies to patients on second generation TKIs, because, as mentioned earlier, Patients who meet all the relevant benchmarks in the first 12 months are monitored periodically using FISH and molecular testing 
| M A NA GE M EN T OF T KI RE SI STA NC E
A remaining problem with the widespread use of all commercially avail- 
| Second and third generation TKIs
Before their approval to treat first-line CML-CP, both nilotinib and dasatinib were approved for use in second-line CML-CP following prior therapy including imatinib. 75, 76 Clinical studies of second-line and third line TKIs are summarized in Table 7 . Based on these studies, several noteworthy ideas have emerged. First, second-line treatment with nilotinib, dasatinib, or bosutinib can yield high rates of response in patients who have inadequate response to imatinib, including high rates of MMR. Second, dose escalation of imatinib can improve response rates in patients with inadequate response to standard-dose imatinib, 77 but switching to second-line TKI is more effective. 78 Several studies that evaluated second-line nilotinib 79, 80 , dasatinib 78, 80 , or bosutinib 81 , and high-dose imatinib (400 mg BID) have demonstrated significantly higher rates of CHR, CCyR, and MMR with the newer TKIs than with high-dose imatinib. Moreover, PFS in these studies was better with the newer TKIs than with high-dose imatinib. Earlier switch to second-line TKI may be more effective than later switch. In the TIDEL-II study, patients who had suboptimal response to imatinib and were switched to nilotinib had a higher rate of CMR at 12 months than patients who had dose escalation of imatinib prior to being switched to nilotinib. 82 In a retrospective pooled analysis of three clinical studies of second-line dasatinib for patients resistant to or intolerant of imatinib, patients who were switched to dasatinib after the loss of MCyR (early intervention group) had higher rates of CHR, CCyR, and MMR, as well as 24-month EFS, TFS, and OS, than patients who were switched after the loss of both MCyR and CHR (late intervention group). 83 Although this analysis included studies with distinct study designs and various dosing schedules of dasatinib, the essential finding was that earlier switch to dasatinib was associated with better outcomes.
Bosutinib was initially studied in patients who had resistance to or intolerance of imatinib. 81 After a dose escalation period, 500 mg once daily was selected as the phase II dose, with the potential for dose escalation to 600 mg once daily for patients not meeting predefined benchmarks. A total of 288 patients were enrolled in the pivotal phase II trial; more than two thirds had imatinib-resistant disease. The primary endpoint of MCyR at 6 months was achieved in 31%; 41% achieved a CCyR. Bosutinib appeared to retain activity across most known mutations that confer imatinib resistance, except for T315I. Responses were independent of whether patients had resistance to or intolerance of imatinib. The most common toxicities were diarrhea, nausea, vomiting, and rash. Diarrhea occurred in 84% of patients, with 9% experiencing grade 3 diarrhea (there were no grade 4 events documented). Other notable adverse events included myelosuppression and liver function test abnormalities.
Ponatinib is a third generation TKI, and the first TKI in class to exhibit activity against CML with T315I mutation. 84 It is 500 times as potent than imatinib at inhibiting BCR-ABL1. 85 The approval of ponatinib was based on the phase II PACE trial, where 449 patients with heavily pretreated CML or Ph-positive acute lymphoblastic leukemia (ALL) were treated. 86 Patients were considered for this trial if they had resistance to or intolerance of dasatinib or nilotinib, or if they had CML with T315I mutation. The dose of ponatinib was 45 mg once daily, and patients were stratified by the disease phase, and the presence or absence of a T315I mutation. Of the 267 patients who received ponatinib in CML-CP, 56% achieved a MCyR by 12 months, which included 45/64 (70%) patients with a T315I mutation. Patients responded more favorably if they had received fewer TKIs. After a median follow up of 5 years, 60% of patients achieved MCyR (primary endpoint) at any time; 82% of those remained in MCyR at 5 years. 87 Furthermore, 40%
of patients achieved a MMR or better. The 5-years survival rate was 73%. 87 Arterial occlusive events occurred in 31% of patients (26% serious). The most common all-grade treatment-emergent adverse events occurring in ! 40% of patients with CML-CP were abdominal pain (46%), rash (46%), thrombocytopenia (45%), headache (43%), constipation (41%), and dry skin (41%). 87 Other notable toxicities include severe skin rashes (4%-7%), pancreatitis (7%), and severe hypertension (20%).
As of early 2014, ponatinib labeling included a revised warning regarding the risk of thrombotic events (13% per year), vascular occlusions, heart failure, and hepatotoxicity, revised dosing information and indications limited to adults with T315I mutation and those for whom no other TKI is indicated. 88 Vascular occlusive adverse events were more frequent with increasing age and in patients with a prior history of ischemia, hypertension, diabetes, or hyperlipidemia. 87 Factors associated with an increased risk of vascular occlusion events include older age, higher dose, history of myocardial infarction or prior vascular events, and longer duration of CML. 87 Studies assessing lower doseschedules of ponatinib are ongoing. In the community practice, it may be safer to use ponatinib 30 mg daily (and lower the dose to 15 mg daily for toxicities) rather than the FDA approved dose of 45 mg daily.
ABL001 (asciminib) is a small molecule allosteric BCR-ABL1 kinase
inhibitor that occupies the myristoyl pocket, leading to a kinase autoinhibition conformation. 89 ABL001 was designed to inhibit BCR-ABL1 in a non-ATP-competitive manner to maintain activity against BCR-ABL1 AP, accelerated phase; BP, blast phase; CHR, complete hematologic response; CP, chronic phase; LyBP, lymphoid blast phase; MaHR, major hematologic response; MyBP, myeloid blast phase; NEL, no evidence of leukemia; NR, not reported.
mutations that confer resistance to TKIs. Preclinically, combined with ATP-competitive TKIs, ABL001 eliminates early leukemic progenitors and diminishes emergence of resistant clones. 89 One hundred and one patients with relapsed refractory CML and Philadelphia-positive acute lymphoblastic leukemia were treated in a phase I trial. 90 For patients lacking these mutations, the choice should be on preexisting conditions, toxicity profiles, and cost.
Bosutinib can be used for patients with most known mutations that lead to imatinib failure. 81 Like dasatinib and nilotinib, bosutinib is not activie against T315I. Bosutinib may be a reasonable choice for patients who fail imatinib who are not good candidates for dasatinib or nilotinib.
Bosutinib has a relatively distinct toxicity profile from the other TKIs, with the predominant problem being diarrhea and other gastrointestinal complaints. Recently, an analysis was conducted to closely characterize the toxicity of bosutinib and the management strategy. 95 At MDACC, post imatinib failure, the choice of second or third generation TKI is based on the disease phase, mutation profile, and patient's comorbidities. In advanced phases, we favor a combination of chemotherapy and TKI (mainly ponatinib or dasatinib). In patients with CML-CP with T315I mutation, ponatinib will be the first choice followed by allo-SCT if a donor is available and an optimal response is not achieved. Outside the context of T315I mutations, the type of mutation will dictate the choice of therapy. Of note, patients with compound mutations may not respond well to second generation TKI. A close monitoring should be offered. 96 If an optimal response is not achieved, a switch of therapy to a third generation TKI and/or allo-SCT is warranted. In patients with no mutation or a mutation sensitive to all second generation TKIs, the choice will be based on comorbidities.
Patients with vascular risk factors and metabolic dysfunctions are not candidates for nilotinib. Patients with lung injuries are not candidates for dasatinib. Bosutinib may be the best choice for patients with cardiac problems and arrhythmias.
| Allogeneic stem cell transplantation (allo-SCT)
The number of patients undergoing allo-SCT for CML-CP has decreased significantly since TKIs were introduced, but will start to increase again as the prevalence of CML increases, as about 2% of patients become resistant to many TKIs every year and require allo-SCT. Allo-SCT has a more important role when patients evolve into AP/BP (see below). Allo-SCT remains an important therapeutic option for patients in CML-CP whose CML has progressed after at least 2 TKIs, and those who potentially harbore the T315I mutation (after a trial of ponatinib therapy). imatinib treatment discontinued TKI therapy and were followed prospectively. 101 Forty-two patients (61%) experienced molecular relapse, all but 2 within 6 months of TKI discontinuation. After reintroduction of imatinib, 26 patients again achieved CMR; the other 16 patients had decreases in BCR-ABL1 levels. Similar results were observed in the comparably designed TWISTER study. 102 Among the 40 patients enrolled, the actuarial estimate of stable treatment-free remission (TFR) was 47% at 2 years; all patients were sensitive to imatinib re-treatment.
Higher TFR rates can be achieved with second-generation TKIs due to the relatively deeper and more sustained molecular responses achieved with these agents compared to imaitnib. 29, 38 In the ENESTfreedom study, TKI discontinuation was evaluated in patients with chronic phase CML who had achieved at least MR4.5 after !2 years of frontline nilotinib therapy, followed by 1 year of nilotinib consolidation.
Nilotinib was reinitiated in patients who lost MMR. Among 190 patients who entered the TFR phase, 98 patients (51.6%) remained in MMR or better at 2 years after stopping nilotinib. Similar to the experience with imatinib, the vast majority of patients were able to regain a deep molecular response after nilotinib reinitiation, although it is notable 11.6% of patients were unable to regain MR4.5 after resuming nilotinib. In the STOP 2G-TKI study, patients receiving first-line or subsequent dasatinib or nilotinib for !3 years and who were in MR4.5
with undetectable BCR-ABL1 transcripts for the preceding 2 years were eligible for TKI discontinuation. 103 The 2-year TFR rate was 53.6%, and among patients who experienced molecular relapse and had to reinitiation TKI therapy, all patients were able to achieve MR4.5 again.
Similar results were observed in the EURO-SKI trial, the largest study to date of TKI discontinuation in CML. 104 In this study of 821 patients with CML treated with frontline imatinib, nilotinib or dasatinib, who had achieved at least MR4, and who subsequently stopped TKI therapy, the molecular recurrence-free survival at 2 years was 52%.
Among 321 (86%) patients who lost their MMR and were restarted on TKI, 81% regained a molecular response (MMR/MR4). In a multivariate analysis, duration of MR4 for 31 years was the only significant factor for persistent deep molecular response after stopping therapy. Additional factors include duration of TKI therapy for 61 years. 105 The relatively higher TFR rates observed with patients initially treated with second-generation TKIs suggests that second-generation TKIs may be preferred as initial therapy for patients in whom eventual TKI discontinuation may be particularly valued (e.g., younger patients expected to live more year benefitting from TKI discontinuation). 106 However, when factoring in the number of patients who achieve deep enough molecular responses to be candidates for stopping TKI therapy, the incidence of molecular cure remains relatively low, ranging from approximately 15% with imatinib to 25%-30% with second-generation TKIs. Although the use of second-generation TKIs certainly increases the likelihood of obtaining a sufficiently deep molecular response to consider TKI discontinuation, the use of these second-generation agents comes at significant financial cost. It has been estimated that the use of frontline second-generation TKIs results in an increased cost of $800 000 per quality-adjusted life-year, compared to generic imatinib. 107, 108 The financial burden associated with frontline use of second-generation TKIs should therefore be carefully weighed against the marginal improvement in cure fraction compared to imatinib.
Although it is encouraging that some patients may be functionally cured with long-term TKI therapy, alternative strategies should be explored to increase the cure fraction of patients with CML. These approaches should focus on both inducing deeper molecular responses and targeting the CML stem cell. Despite the presence of a constitutively active BCR-ABL1 kinase, these leukemic stem cells may be quiescent, which renders them relatively resistant to TKI therapy. 109 The presence of resistant leukemic stem cells, in part, explains why a substantial proportion of patients rapidly relapse when TKI therapy is stopped. Future TKI-independent therapeutic approaches that target the leukemic stem cell will be imperative to increasing the number of patients with CML who can be cured. 117 The hope is that these novel strategies will lead to deeper and more durable responses than TKI therapy alone and will therefore facilitate functional cure in a higher proportion of patients with CML than does single-agent TKI therapy.
TKIs discontinuation studies in patients with durable CMR demonstrate that stopping TKI therapy is feasible, and some patients may be cured. At MDACC, therapy discontinuation is offered only for patients in chronic phase with a quantifiable transcript, who have been on TKI for at least 6 years, have achieved a sustained CMR for at least 3-4 years, and in whom a close follow-up can be performed (Table 8) .
Going forward, it is important to continue to investigate the possibility of safe treatment cessation. Measures of quality of life and adverse event avoidance should be studied in subsequent trials. The economic impact of long-term discontinuation of imatinib is substantial.
| A DV A N CED STA G E C M L
Patients with CML-AP or CML-BP may receive initial therapy with TKIs (newer generation TKIs like dasatinib or ponatinib preferred over imatinib) to reduce the CML burden, and be considered for early allo-SCT.
118-122
Response rates with combinations of TKIs and chemotherapy are 40% in nonlymphoid CML-BP and 70%-80% in lymphoid CML-BP. [123] [124] [125] Median survival times are 6 to 12 months, and 12 to 24 months, respectively. The addition of TKIs to chemotherapy has improved the response rates and prolonged the median survival time in CML-BP. We recently assessed outcome of 477 patients with CML-BP who were treated with a TKI at some point during the course of their CML. 126 The median overall survival was 12 months and the median failure-free survival was 5 months. The combination of a TKI with intensive chemotherapy followed by stem cell transplantation appeared to confer the best outcome. This may represent a considerable burden on patients and the healthcare systems in relation to drug availability, compliance, potential development of long-term side effects, and costs. Therefore it is important to continue research into therapies that increase the rates of durable
CMRs. This may be achievable with the current more potent new generation TKIs alone, or in combination with other available (Bcl-2 inhibitors, peg-interferon alpha-2, omacetaxine, decitabine) or investigational therapies (JAK2 inhibitors, hedgehog inhibitors, stem cell poisons, vaccines). Such strategies may improve the eradication of minimal residual disease, potentially obviating the need for indefinite therapy with TKIs.
Further understanding of the pathophysiologic events downstream of 
| M D A N DE RSON C AN CE R CEN TE R A P P R OAC H
ALL patients suspected to have CML undergo bone marrow examination which will confirm the diagnosis and provide information needed for staging. Baseline PCR is performed to identify the specific type of rearrangement that can be appropriately followed when assessing for response to TKI therapy.
Waiting for confirmation, patients are placed on transient cytore- 
